VB-201

DB15259InvestigationalSmall molecule

VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).

Mechanism: Pharmacologically active on Toll-like receptor 2 and Monocyte differentiation antigen CD14
Curator reviewed
Formula / weight: C₂₉H₆₀NO₈P · 581.772 g/mol (avg)
Code names: VB-201

Resolves to

Compound

Structure

InChIKeyJGGNOCUEWOGWPL-MUUNZHRXSA-NSMILESCCCCCCCCCCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OCCCCC(O)=O

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with VB-201, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.